Medical/Pharmaceuticals
China recalibrates its COVID-19 response strategy
BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...
2022-12-12 10:22
2530
Innovent Presents Phase 1b Clinical Data of IBI188 (Anti-CD47 Monoclonal Antibody) at the 2022 American Society of Hematology Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, Dec. 11, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology an...
2022-12-11 08:00
6370
Goodwin Biotechnology Inc. is now GBI, as Part of their Rebranding Initiative on their 30-Year Anniversary!
PLANTATION, Fla., Dec. 10, 2022 /PRNewswire/ -- Goodwin Biotechnology, Inc. announces its new name, GBI, as part of a rebranding initiative to commemorate its 30-year anniversary. This includes a new name, logo and website to reflect its evolution from an early-stage clinical manufacturing Contra...
2022-12-10 04:16
3735
Treadwell Therapeutics Announces A Presentation at the 2022 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor
NEW YORK, Dec. 9, 2022 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that data presented on the ongoing CFI-402257-CL-001 clinical study of the Company's CFI-402257 program in advanced solid...
2022-12-09 22:30
7855
SmartCardia Earns Frost & Sullivan's 2022 Global New Product Innovation Award in the Cardiac-monitoring Wearables Industry
The company's innovative real-time monitoring system ensures that patients are treated effectively and efficiently. SAN ANTONIO, Dec. 9, 2022 /PRNewswire/ -- Based on its recent analysis of the cardiac-monitoring wearables market,Frost & Sullivan recognizes SmartCardia with the 2022 Global New P...
2022-12-09 18:00
3310
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors
* Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting the Tumor Associated Antigen (TAA) Claudin 18.2 * The Phase I trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 as a monotherapy in patients withadvanced or...
2022-12-09 08:30
3989
Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and ...
2022-12-09 08:00
4592
Innovent Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress
ROCKVILLE, Md. and SUZHOU, China, Dec. 9, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-12-09 08:00
4772
TrialWire Awarded by Frost & Sullivan for Innovative Clinical Trial Patient Recruitment Technology Platform
TrialWire delivers superior trial patient recruitment solutions based on highly sophisticated information technology (IT) all in one secure platform SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Based on its recent analysis of the clinical trial patient recruitment IT solutions industry,Frost & Sulli...
2022-12-08 22:00
3875
SonarMed™ airway monitoring system Applauded by Frost & Sullivan for Providing Real-time Visualization for Accurate Troubleshooting with Its Endotracheal Tube Airway Monitor
The SonarMed™ system is the first and only FDA-cleared airway monitoring system that provides heightened patient safety, cost savings, and quality measures while lowering average LOS in the NICU. SAN ANTONIO, Dec. 8, 2022 /PRNewswire/ -- Frost & Sullivan recently assessed the neonatal care indus...
2022-12-08 21:00
2664
Antengene Appoints Amily Zhang as its Chief Medical Officer
SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
2022-12-08 08:30
4526
HARRISON.AI NAMED ON THE 2022 CB INSIGHTS' DIGITAL HEALTH 150 LIST
The clinician-led technology platform has been recognized for achievements in
computer-aided imaging
NEW YORK, Dec. 8, 2022 /PRNewswire/ -- CB Insights
2022-12-08 06:00
3184
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023 --Phase I clinical trial will also determine if ASC11 needs to be boosted by ...
2022-12-07 18:10
4838
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
Leniolisib was well tolerated and significant improvement over placebo was notable in the co-primary endpoints, reflecting a favorable impact on patients' immune dysregulation and deficiency The peer-reviewed publication heightens international understanding of APDS, a rare and recently characte...
2022-12-07 14:00
4493
Apollo Proton Cancer Centre successfully performs Asia's 1st Brain Bypass Surgery on twin children with Moya Moya Disease
CHENNAI, India, Dec. 7, 2022 /PRNewswire/ -- Apollo Proton Cancer Centre (APCC) recently performedAsia's first brain bypass surgery on twin 8-year-old children fromthe Netherlands. The integration of advanced technology and expertise at APCC helped the children to undergo surgery and recover quic...
2022-12-07 13:17
3957
PGTG successfully develops SGF bone-derived factor to restore the skeletal system
BEIJING, Dec. 7, 2022 /PRNewswire/ -- The bone-derived skeletal growth factor (SGF), jointly developed by a research facility under the direction of leading biochemist, academician and researcher Zhao Yufen and theAnhui-based research center of one of the world's health industry leaders People's ...
2022-12-07 12:00
2589
SmartFuture launches SDK to enable plug-and-play Remote Patient Monitoring in existing healthcare payer and provider applications
SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- SmartFuture, a leading health-tech company and provider of integrated RPM (Remote Patient Monitoring) solutions, has launched anRPM SDK (Software Development Kit) product. SmartFuture's RPM SDK product allows healthcare providers and payers to integrate wh...
2022-12-07 10:36
3564
Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program
Practical, innovative functionality seeks to alleviate eCOA burdens, reduce time-to-launch, and improve site, clinician, and patient experience. PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic ar...
2022-12-07 08:00
3044
Veeva Pulse Shows Digitally Enabled Field Teams are Using HCP Time More Effectively in Asia Pacific
HCP Access is selective as nearly half meet with only one company monthly
SINGAPORE, Dec. 7, 2022 /PRNewswire/ -- Veeva Systems
2022-12-07 08:00
4569
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
SYDNEY, Dec. 7, 2022 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today commenced its previously announced backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights O...
2022-12-07 07:00
4260
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21The Coffee Bean & Tea Leaf® Turns 63 and Sets a New Direction for Its Next Chapter of Growth
[Picked up by 263 media titles]
2026-10-05 13:24
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9147
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8215
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8152